Gilead Sciences, Inc. v. Mylan Pharmaceuticals Inc.
1:17-cv-00187
Overview
Parties
Defendant
Mylan Pharmaceuticals Inc. Operating Company
Represented By
1 Attorneys ListedDevlin Law Firm
1526 Gilpin Avenue, 19806
Plaintiff
Gilead Sciences, Inc. Operating Company
Represented By
7 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° Radar 8 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| πΊπΈ United States | US 8,148,374 B2 Asserted | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 8,486,942 B2 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2014001719 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2015013994 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2016006991 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 2017015864 | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 90,322,807 P | US Continuation / Sibling | View Official Patent → |
| πΊπΈ United States | US 95,871,607 P | US Continuation / Sibling | View Official Patent → |
No active co-pending lawsuits found across other jurisdictions for this family. All related sibling filings are currently unlitigated.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US8148374
Modulators of pharmacokinetic properties of therapeutics
|
Filed: 2008-02-22
Issued: 2012-04-03
|
Active (2.8 yrs remaining)
+559d PTA
Expires: 2029-09-03
|
Patent Enforceability & Injunction Risk Assessment
Active Threat β Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.
High PTA (+559 days) / Cellect Scrutiny β Over 559 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
2
Dispositive
0
Granted
0
Denied
0
Pending / Review
1
Motions by Category
Key Dispositive Motions & Rulings